Key facts
- This page summarizes Gulsen Kama's Form 4 filing for Bionano Genomics, Inc. (BNGO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Jun 2024, 17:48.
Gulsen Kama - 03 Jun 2024 Form 4 Insider Report for Bionano Genomics, Inc. (BNGO)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- BNGO
- Reported as of
- 03 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jun 2024, 17:48:08 UTC
- Prior SEC filing
- 20 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan V. Dixon, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Gulsen Kama filed Form 4 for Bionano Genomics, Inc. (BNGO) on 05 Jun 2024.
Change
- Previous filing in this sequence was filed on 20 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BNGO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +16,000
- Change %
- Price
- $0.000000
- Shares after
- 16,000
- Date
- 03 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BNGO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 03 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- $0.9300
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan.
Footnote F2
The shares subject to the RSUs vest 1/4th annually beginning on the one-year anniversary of the grant date.
Footnote F3
The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of June 3, 2024 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date.